重组人γ-干扰素雾化吸入辅助治疗耐多药结核病的近期疗效观察

目的观察和评价重组人γ-干扰素(IFN-γ)辅助治疗耐多药结核病（MDR-TB）的疗效。方法将60例MDR-TB患者采用计算机随机分组方法分为治疗组、对照组各30例。采用3SpPaZETH/9SPPE方案治疗（Sp：司帕沙星，Pa：力克菲蒺，Z：吡嗪酰胺，E：乙胺丁醇，TH：丙硫异烟胺），治疗组在加强期加用IFN-γ雾化吸入2个月。结果共有57例患者完成疗程。治疗组28例,痰菌阴转率82.1%，对照组29例, 痰菌阴转率58.6%(P<0.05)，治疗组病灶显效率92.9%,优于对照组(P<0.01)。治疗组治疗3个月时CD4、CD4/CD8较对照组提高(P<0.05)。IFN-γ雾化吸入无严重不良反应。结论重组人γ-干扰素可辅助治疗耐多药结核病，是一种安全、可靠的生物制剂。

A short-term efficacy on aerosolizing inhalation recombinant human gamma interferon in multidrug-resistant pulmonary tuberculosis

Objective To observe and evaluate the clinical efficacy of recombinant human IFN-γ in multidrug resistant pulmonary tuberculosis （MDR-TB）. Methods Sisty cases with MDR-TB were randomized into a treatment group（30 cases treated with 3SPPZETH4-（2）IFN γ/9SPPE） and a control group（30 cases treated with 3SpPaZETH/9SpPaE）. IFN-γ was used by aerosilizing inhalation in initial phase of the treatment group for two months. Results 28 cases in the treatment group and 29 cases in the control group completed the treatment course. The sputum negative conversion rate in the treatment group（82.1%）was higher than that in the control group（58.6 % ）（P〈 0.05）. The rate of radiographic improvement in the treatment group（92.9%） was higher than that in the control group（P〈0.01）. CD4 T cells count and the ratio of CD4/CD8 in the treatment group were higher than that in the control group at the 3nd month of therapy （P〈0.05）. There was no severe adverse effects of IFN-γ therapy. Conclusions As an effective and relatively safe biological agent, IFN-γ can be used to adjuvant therapy in multidrug resistant pulmonary tuberculosis.